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What is known about the subject?
 ► Identifying serious bacterial infections (SBIs) is a 
major diagnostic challenge.
 ► A combination assay (tumour necrosis factor-relat-
ed apoptosis-inducing ligand, interferon γ induced 
protein-10 and C reactive protein) can differentiate 
accurately between viral and bacterial infections.
 ► Clinical prediction models that also include biomark-
ers, such as the Feverkidstool, are helpful in predict-
ing SBIs.
What this study adds?
 ► The diagnostic accuracy of the Feverkidstool in-
creases when updated with the combination assay 
to predict SBIs.
 ► The Feverkidstool with the combination assay ben-
efits children with low–moderate risk estimates for 
pneumonia or other SBIs in particular.
 ► Combining a clinical risk profile (like the 
Feverkidstool) with a new biomarker contributes to 
positioning that biomarker in the diagnostic workup.
AbstrACt
Objective To determine whether updating a diagnostic 
prediction model by adding a combination assay (tumour 
necrosis factor-related apoptosis-inducing ligand, 
interferon γ induced protein-10 and C reactive protein 
(CRP)) can accurately identify children with pneumonia or 
other serious bacterial infections (SBIs).
Design Observational double-blind diagnostic study.
setting Two hospitals in Israel and four hospitals in the 
Netherlands.
Patients 591 children, aged 1–60 months, presenting 
with lower respiratory tract infections or fever without 
source. 96 of them had SBIs. The original Feverkidstool, 
a polytomous logistic regression model including clinical 
variables and CRP, was recalibrated and thereafter updated 
by using the assay.
Main outcome measures Pneumonia, other SBIs or 
no SBI.
results The recalibrated original Feverkidstool 
discriminated well between SBIs and viral infections, 
with a c-statistic for pneumonia of 0.84 (95% CI 0.77 to 
0.92) and 0.82 (95% CI 0.77 to 0.86) for other SBIs. The 
discriminatory ability increased when CRP was replaced 
by the combination assay; c-statistic for pneumonia 
increased to 0.89 (95% CI 0.82 to 0.96) and for other SBIs 
to 0.91 (95% CI 0.87 to 0.94). This updated Feverkidstool 
improved diagnosis of SBIs mainly in children with low–
moderate risk estimates of SBIs.
Conclusion We improved the diagnostic accuracy of the 
Feverkidstool by replacing CRP with a combination assay 
to predict pneumonia or other SBIs in febrile children. The 
updated Feverkidstool has the largest potential to rule out 
bacterial infections and thus to decrease unnecessary 
antibiotic prescription in children with low-to-moderate 
predicted risk of SBIs.
IntrODuCtIOn
Suspicion of infectious disease is one of the 
most common causes of paediatric emergency 
department (ED) visits.1 The proportion of 
bacterial infections in children with fever 
without source (FWS) and acute respiratory 
tract infections (RTIs) is however low (respec-
tively 0.02%–13% and 26%–28%).2–4 Next, 
identifying patients benefiting from antibiotic 
treatment remains a major diagnostic chal-
lenge. Consequentially, children with acute 
RTI receive antibiotics almost twice as often 
as the estimated prevalence.2 5 6 Antibiotic 
overuse is associated with increased antibiotic 
resistance, causing 25 000 deaths in Europe 
annually.7 8 This underlines the need to better 
differentiate between viral and bacterial infec-
tions. Therefore, several prediction models 
have been developed.9 10 The Feverkidstool, a 
clinical prediction model including both clin-
ical parameters and C reactive protein (CRP), 
is a validated tool for supporting clinical 
decision-making on, for example, whether 
or not to start antibiotics.11–13 However, 
further improvement of this diagnostic tool is 
warranted as it does not provide an accurate 
diagnosis for all patients.
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We recently showed that a novel blood assay, combining 
concentrations of CRP with tumour necrosis factor-re-
lated apoptosis-inducing ligand (TRAIL) and interferon 
γ induced protein-10 (IP-10), could diagnose bacterial 
infections more accurately than CRP alone.14–16
The dynamics of TRAIL are complementary to tradi-
tionally studied bacteria-induced proteins; TRAIL concen-
trations decrease in bacterial infection and increase in 
viral infections.15 The aim of this study is to investigate 
whether updating the Feverkidstool by replacing CRP 
with the combination assay can improve the diagnosis of 
serious bacterial infections (SBIs) in preschool children.
PAtIents AnD MethODs
The current study builds on the prospective observational 
OPPORTUNITY Study performed in four hospitals in the 
Netherlands and two hospitals in Israel between 16 October 
2013 and 28 January 2015. For detailed methods, we refer 
to the original publication.14 In short, this study included 
clinical data, a host-protein-based assay, nasal swab PCR and 
28-day follow-up data from children aged 1–60 months with 
lower RTI or FWS (n=777). The study was an observational 
double-blind diagnostic study. The analysis of the serum 
samples for the assay (index test) was done in the absence 
of any clinical or other patient-related information, and the 
expert panel (reference standard) was blinded to the deci-
sions of their peers and to the results of the index test.
General inclusion and exclusion criteria can be found 
in the original publication that had 577 children in the 
primary analysis. We added to our current study data of 
children aged 1–2 months that in the original OPPORTU-
NITY Study were included for a subanalysis (n=28), as this 
study showed accurate results of the assay in this popula-
tion. Children admitted to the intensive care (all referred 
from the wards of other hospitals, n=14) were excluded 
as the Feverkidstool was developed for febrile patients 
presenting at the ED (online supplementary figure 1). 
Parents gave written informed consent prior to sampling. 
This study was designed and analysed without patient 
involvement. Patients were not invited to contribute to 
the writing or editing of this document for readability or 
accuracy. This manuscript follows the TRIPOD (Trans-
parent reporting of a multivariable prediction model for 
individual prognosis or diagnosis)(online supplementary 
file 3) reporting guidelines.
Prediction model
The Feverkidstool is a polytomous prediction model that 
predicts the risk of pneumonia or other SBIs, based on 
the following variables: age, body temperature, heart 
rate, respiratory rate, oxygen saturation, ill-appearance, 
peripheral capillary refill, chest wall retractions and CRP 
(definitions presented in the statistical analysis plan, 
online supplementary file 1).12
Combined host-protein-based assay
The assay is currently ELISA-based (a point-of-care test 
is being developed) and combines the concentrations 
of TRAIL, IP-10 and CRP using a predetermined logistic 
regression formula to compute the likelihood score 
(scale 0–100) for a bacterial infection.14 15 The assay was 
performed on coded serum samples in the absence of 
any patient-related information.
reference standard diagnosis
Currently, no single reference standard test exists for 
determining the aetiology of an infection.17 There-
fore, in the OPPORTUNITY Study, England’s National 
Health Service standard for evaluating diagnostic tests 
was followed and an expert panel reference standard was 
composed.14 18 Every recruited patient was diagnosed by 
three panel members affiliated to the country of recruit-
ment using all available electronic Case Record Form 
(eCRF) information (clinical and laboratory information, 
including a 28-day follow-up), but blinded to the assay 
and Feverkidstool results and to the labels of their peers. 
Each expert assigned one of the following aetiologies to 
each patient: bacterial infection, viral infection, mixed 
infection (ie, bacterial and viral co-infection), non-in-
fectious disease or indeterminate. Patients assigned as 
mixed infection were later classified as bacterial because 
they are clinically managed similarly. Patients with a 
bacterial reference standard diagnosis were divided 
into pneumonia or other SBIs (eg, meningitis, urinary 
tract infections, bacteraemia) based on the diagnosis at 
hospital discharge assigned by the attending physician.
statistical analysis
General approach
We compared the diagnostic accuracy to predict SBIs of 
the original Feverkidstool with the accuracy of the Fever-
kidstool updated with the assay (hereafter called updated 
Feverkidstool). Statistical analyses were performed in 
SPSS V.21.0 for Windows and R V.3.2.2. We used the 
Mann-Whitney U test for comparison of continuous vari-
ables. Categorical outcomes were analysed using the χ2 
test or Fisher’s exact test where expected cell counts were 
less than 5.
Model development and performance
First, we recalibrated the original Feverkidstool on our 
data using two separate logistic regressions, one for pneu-
monia and one for other SBIs (recalibrated Feverkidstool: 
logit (pneumonia or other SBI)= β
0
 + β
1
 (linear predictor 
Feverkidstool)). Then, we updated the Feverkidstool by 
adding the combination assay (updated Feverkidstool: 
logit (pneumonia or other SBI) = β
0
 + β
2a
 (linear predictor 
Feverkidstool) + β
2b
 (score assay)). One element of the 
assay, CRP, was also a predictor in the linear predictor 
Feverkidstool. To be able to compare the effect of using 
the assay (updated Feverkidstool) instead of the CRP 
only (original Feverkidstool), we standardised the effect 
of the CRP coefficient (as part of the linear predictor 
Feverkidstool) in this updated Feverkidstool. There-
fore the linear predictor Feverkidstool was based on the 
median CRP value for all participants. The actual CRP 
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value of patients was used to compute the score assay. 
Detailed models are presented in the statistical analysis 
plan (online supplementary file 1). The discriminative 
ability of the recalibrated original and updated models 
was expressed using pairwise c-statistics.19
Predicted risk thresholds
To help interpret the potential benefit of the different 
models along the range of predicted probabilities, a 
decision curve analysis (DCA) was performed. The DCA 
assesses the relative harm of false positives and false nega-
tives for different probability thresholds if the models 
were used to guide antibiotic prescription.20 For prede-
fined risk thresholds, we calculated sensitivity, specificity, 
positive and negative predictive values, and positive and 
negative likelihood ratios (LR+, LR−) for the original and 
updated models.
Reclassification
To assess the potential added value of the updated Fever-
kidstool in correctly classifying SBIs and viral infections 
using defined thresholds, we did a head-to-head compar-
ison for the updated Feverkidstool and the recalibrated 
original Feverkidstool in a reclassification table.21
Missing values
Multiple imputation techniques enabled analysing all 
available data. Missing values in the variables, needed 
for the Feverkidstool, were imputed 10 times using the 
multivariate imputation by chained equations (MICE) 
algorithm in R statistical software.22 Variables used in the 
imputation model are presented in the statistical anal-
yses plan (online supplementary file 1). Analyses were 
performed separately in the 10 imputed data sets and 
combined using Rubin’s rules.23 The Feverkidstool vari-
able peripheral capillary refill was not recorded in the 
OPPORTUNITY Study for any patient. Because we had 
no information on the distribution of values for capillary 
refill, we could not include this variable in the model for 
multiple imputation. Leaving the coefficient for capillary 
refill out of the Feverkidstool would have led to systematic 
lower predictions (biassed calibration), so we replaced 
this systematic missing variable by the mean prevalence of 
prolonged capillary refill in the initial Feverkidstool deri-
vation cohort (=0.039, mean imputation).24 Inconclusive 
diagnoses (n=71) were also imputed; a sensitivity analysis 
was performed leaving out patients with an inconclusive 
diagnosis.
results
Population characteristics
A total of 591 patients was available for analysis: 30 pneu-
monia, 66 other SBIs and 495 viral infections (online 
supplementary figure 1). Children with pneumonia were 
older than children with other SBIs or with viral infec-
tions (median age of 24.5 vs 15 months) and children 
with pneumonia or other SBIs were hospitalised more 
often (73% and 77%) than children with viral infections 
(52%, table 1). Children with an inconclusive reference 
standard diagnosis differed from children with a conclu-
sive diagnosis on age, biomarker values and antibiotic 
prescription (online supplementary table 1).
Model performance
The recalibrated original Feverkidstool discriminated 
well between pneumonia and other infections (c-statistic 
0.84, 95% CI 0.77 to 0.92), and between other SBIs and 
other infections (c-statistic 0.82, 95% CI 0.77 to 0.86, 
online supplementary figure 2). This performance is 
similar to previous Feverkidstool validations.11 12 Updating 
the Feverkidstool with the assay improved discrimination 
between bacterial and other infections, reflected by an 
improved c-statistic for pneumonia to 0.89 (95% CI 0.82 
to 0.96), and for other SBIs to 0.91 (95% CI 0.87 to 0.94) 
(online supplementary figure 2). A sensitivity analysis 
of the cohort without imputed reference standard diag-
noses showed similar results, with improved prediction of 
pneumonia and other SBIs (online supplementary table 
2).
Predicted risk thresholds
The DCA shows the net benefit of starting antibiotics 
using predictions of the updated instead of the orig-
inal Feverkidstool, depending on the choice of proba-
bility threshold. Children with low–moderate predicted 
risks ≤40% for pneumonia or other SBIs had the most 
benefit from the updated Feverkidstool (figure 1). For 
example, if all children with a predicted risk of >20% 
would be treated with antibiotics, the net benefit of the 
updated Feverkidstool increases with 0.2 from the 0.2 
net benefit in the original feverkidstool for predicting 
pneumonia to 0.4 net benefit. For predicting other SBI 
the net benefit increases from 0.1 (original Feverkid-
stool) to 0.5 by the updated Feverkidstool. In absolute 
numbers this would mean that by using the updated 
Feverkidstool at a threshold of 20%, we achieve 20 
or 50 more correct treatment decisions (out of 100 
patients) than when using the original Feverkidstool. 
Table 2 gives more detailed insight on the effects of the 
updated model in diagnostic value using several thresh-
olds. Using a rule of thumb of LR+ of 5 and LR− of 0.2,25 
thresholds of 10% and 2.5% using the updated model 
seem better applicable for ruling in and out of both 
pneumonia and other SBIs.
reclassification
Table 3 shows the clinical consequences if the updated 
Feverkidstool was used instead of the original Feverkid-
stool. In total, the updated Feverkidstool for pneumonia 
reduced the number of children with a falsely predicted 
high or intermediate risk from 234 to 143 (39%) 
compared with the original Feverkidstool, and from 427 
to 197 (54%) for children with other SBIs.
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Table 1 Characteristics of patients included in the primary analysis
Pneumonia
(n=30)
Other SBIs
(n=66)
Viral
(n=495)
Predictor variables
Age (months) 24.5 (12.7–41.3) 15.0 (8.0–33.0) 15.0 (7.0–28.0)
Gender, male 19 (63%) 32 (49%) 280 (57%)
Duration of fever (days) 3 (2–5) 2 (1–4) 2 (1–4)
Temperature (°C) 38.6 (38.2–39.8) 38.7 (37.8–39.4) 38.5 (37.6–39.2)
  n=30 (100%) n=66 (100%) n=493 (99%)
Respiratory rate 50 (34–70) 40 (31–52) 38 (30–52)
  n=15 (50%) n=31 (47%) n=252 (51%)
Tachypnoea 12 (80%) 17 (55%) 130 (52%)
Heart rate 160 (24) 152 (27) 151 (24)
  n=29 (97%) n=57 (86%) n=453 (92%)
Tachycardia 21 (72%) 29 (51%) 232 (51%)
Oxygen saturation (%O
2
) 98 (97–99) 99 (97–100) 98 (96–100)
  n=28 (93%) n=48 (73%) n=417 (84%)
Desaturation (<94%O
2
) 1 (4%) 0 (0%) 24 (6%)
Chest wall retractions 6 (20%) 4 (6%) 60 (12%)
  n=30 (100%) n=63 (95%) n=484 (98%)
Ill appearance 13 (43%) 25 (38%) 141 (29%)
C reactive protein (mg/l) 176 (72–224) 102 (55–151) 15 (5–36)
Assay score 98 (76–100) 88 (68–98) 4 (1–26)
Other variables
Hospital admission 22 (73%) 51 (77%) 255 (52%)
Hospitalisation duration (days) 4 (3–6) 4 (3–5) 3 (2–4)
Antibiotic treatment prescribed 30 (100%) 63 (96%) 140 (29%)
Recruiting site
Secondary care centre 27 (90%) 63 (96%) 463 (94%)
Tertiary care centre 3 (10%) 3 (4%) 32 (6%)
Focus of infection
Central nervous system 0 (0%) 0 (0%) 9 (2%)
Gastrointestinal tract 0 (0%) 1 (2%) 19 (4%)
Other 3 (10%) 11 (17%) 39 (8%)
Respiratory tract 26 (87%) 18 (27%) 250 (50%)
Systemic 0 (0%) 2 (3%) 9 (2%)
Unknown 1 (3%) 10 (15%) 169 (34%)
Urinary tract 0 (0%) 24 (36%) 0 (0%)
Data are presented as n (%), median (IQR) or mean (SD). This table includes imputed reference standard diagnoses, data are based on 1 
of the 10 imputed data sets. If data were not available for all patients, the total number of available data are noted. Clinical syndrome was 
based on the diagnosis of the attending physician at discharge from the hospital. LRTI included pneumonia and bronchiolitis; URTI included 
laryngitis, pharyngitis, otitis media, sinusitis and tonsillitis. LRTI: lower respiratory tract infection; URTI: upper respiratory tract infection
SBI, serious bacterial infection.
DIsCussIOn
In this study, we showed that when a clinical prediction 
model including CRP was updated with a combined host-
protein-based assay, SBIs were predicted more accurately 
in children presenting with a lower RTI or FWS at the 
hospital. We showed that children with low-to-moderate 
predicted risk benefit most from this updated model.
strengths and weaknesses of the study
A strength of the present study is the used combination 
of variables. To our knowledge, this is the first study 
combining clinical parameters with both bacterial and 
viral biomarkers. A second strength is the use of an expert 
panel reference standard, which has the advantage of 
capturing a wide spectrum of illness severities, including 
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Figure 1 Decision curve analysis with the net benefit of 
starting antibiotics to none of the patients (black line), to 
all patients (grey line), the original Feverkidstool (red line) 
and the updated Feverkidstool (blue line), depending on the 
choice of probability threshold for starting antibiotics for 
pneumonia (a) and other SBIs (b). FKT, Feverkidstool; SBI, 
serious bacterial infection.
difficult to diagnose cases, thereby reflecting the diag-
nostic process in clinical practice.26 Another strength is 
the prospective patient recruitment. The ethics commit-
tees approved venous blood sampling even if blood 
sampling was not indicated for routine care. Therefore, a 
wide spectrum of illness severities was captured, including 
difficult to diagnose cases. In addition, a strength of the 
Feverkidstool is its polytomous character. This enables 
the discrimination between different diseases: pneu-
monia and other SBIs versus no SBI.27 Finally, in clinical 
practice different thresholds are needed depending on 
the setting. Therefore we performed DCA to help inter-
pret the differences between the models along the wide 
range of predicted probabilities.20
Limitations of our study should also be addressed. First, 
the number of bacterial cases was relatively low. Therefore, 
it was not possible to refit the individual coefficients for all 
Feverkidstool variables. The aim of the current study was 
to see whether the new assay had additional value to the 
original well validated Feverkidstool rather than to build 
an optimal diagnostic model. Second, one of the Fever-
kidstool variables, capillary refill, was not available for any 
of the participants. Therefore, multiple imputation was 
impossible. Leaving capillary refill out by entering 0 for all 
capillary values would have resulted in an unfair reduction 
of model calibration. We think imputation of the mean 
was the best available option.24 Even though this may have 
limited the discriminative performance of the model, we 
believe the influence is limited, because the dichotomous 
variable capillary refill has little diagnostic value within 
the Feverkidstool. In addition, the aim of the current 
study was to compare the original Feverkidstool with the 
updated model. Imputation of capillary refill values was 
performed similarly for both models, so this had no influ-
ence on the comparison of the models. Third, the reclas-
sification is based on arbitrarily chosen thresholds (2.5% 
and 10%). These thresholds, however, mostly correspond 
with LR that have been reported to be meaningful in 
decisions for febrile children: LR+>5.0 for ruling in SBIs 
and LR−<0.2 for ruling out SBIs.25 Fourth, the Feverkid-
stool includes important clinical variables that are used by 
every physician when deciding whether to start antibiotics 
or not. Following clinical care, during the expert panel 
reference standard process, the panel was provided with a 
wide range of clinical information, including the clinical 
Feverkidstool variables, but they were not informed about 
the algorithm. We, however, cannot exclude that incor-
poration bias—in which part of the test being assessed is 
included in the reference standard—has resulted in some 
degree of overestimation of the outcome. Fifth, due to the 
relatively low number of bacterial cases, some diseases, 
such as bacterial meningitis, were not observed in our 
study cohort. Information to discriminate sepsis from 
bacteraemia cases was not available. Sixth, in the current 
study, none of the ED patients were hospitalised at the 
intensive care unit. Further studies with higher numbers 
of patients with a more severe clinical presentation are 
warranted as especially in these patients early detection 
of a SBI can be critical. Seventh, in this study we wanted 
to study the added value of the assay on top of the model 
that had also undergone impact analysis28 (ie, the original 
Feverkidstool (including CRP)), rather than developing a 
new model. As both the assay and the original Feverkid-
stool contain CRP, we had to solve this. Refitting the Fever-
kidstool’s model without CRP will not provide the answer 
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Table 3 Diagnostic reclassification by the updated Feverkidstool compared with the original Feverkidstool
a.
Reference standard diagnosis:
Pneumonia (n=30)
Reference standard diagnosis:
No pneumonia (n=561)*
Updated Feverkidstool predicted risk 
for pneumonia
Updated Feverkidstool predicted risk for 
pneumonia
Low Intermediate High Low Intermediate High
Original Feverkidstool predicted  
risk for pneumonia‡
Low 3 1 1 304 20 3
Intermediate 1 2 4 100 46 27
High 0 0 18 14 14 33
b.
Reference standard diagnosis:
Other SBIs (n=66)
Reference standard diagnosis:
No other SBIs (n=525)†
Updated Feverkidstool predicted risk 
for other SBIs
Updated Feverkidstool predicted risk 
for other SBIs
Low Intermediate High Low Intermediate High
Original Feverkidstool  
predicted risk for other SBIs§
Low 1 0 0 98 0 0
Intermediate 1 2 6 190 55 25
High 0 4 52 40 51 66
The Feverkidstool classification was compared with the majority reference standard for the prediction of pneumonia (A) and other SBIs (B). Head-
to-head comparison of the original Feverkidstool and the updated Feverkidstool. Predicted risks of pneumonia (A) and other SBIs (B) were low if the 
predicted risk was below 2.5%, intermediate between 2.5% and 10%, and high above 10%.
*As the comparison in this table is between the presence or absence of pneumonia, it should be noted that ‘no pneumonia’ includes viral and other 
SBIs.
†As the comparison in this table is between the presence or absence of other SBIs, it should be noted that ‘no other SBIs’ includes viral and 
pneumonia.
‡Among the patients with pneumonia as determined by the majority in the expert panel, six patients were correctly reclassified as being at higher 
risk using the updated Feverkidstool instead of the original Feverkidstool and one patient was incorrectly reclassified. For patients in whom 
pneumonia was absent, these numbers are respectively 128 and 50. Reclassification improvement was 17% for patients with pneumonia (6 minus 1 
of 30) and 14% for patients without pneumonia (128 minus 50 of 561).
§Among the patients with other SBIs as determined by the majority in the expert panel, six patients were correctly reclassified using the updated 
Feverkidstool instead of the original Feverkidstool and five patients were incorrectly reclassified. For patients in whom other SBIs are absent, these 
numbers are respectively 281 and 25. Reclassification improvement was 2% for patients with other SBIs (6 minus 5 of total 66) and 49% for patients 
without other SBIs (281 minus 25 of 525).
SBI, serious bacterial infection.
to our research question on the added value of the assay 
to the Feverkidstool. In addition, the number of bacterial 
cases was too low to refit the original Feverkidstool. We 
also did not want to simply add the assay as a predictor in 
the Feverkidstool model, as this would downwardly bias 
the assay’s added value. Therefore, we essentially removed 
the effect of the CRP in the Feverkidstool by assigning the 
median value of CRP to the CRP single predictor in the 
Feverkidstool to all patients. To our knowledge, using the 
median CRP value was the best possible approach to avoid 
double counting of CRP. Finally, there were 71 patients for 
whom the expert panel could not assign a final diagnosis. 
Such inconclusive cases are inherent to studies using 
outcomes lacking a gold standard. To make optimal use 
of the data from all recruited patients, we have imputed 
these reference standard diagnoses. As the imputed diag-
noses are used for both the original and the updated 
Feverkidstool, we do not expect this to have influenced 
the results of updating the Feverkidstool. In addition, a 
sensitivity analysis in which all cases with imputed diag-
noses were excluded showed comparable results.
Comparison with existing literature
The study in which the Feverkidstool was developed and 
the OPPORTUNITY Study had comparable inclusion 
criteria. Most importantly, both studies included chil-
dren suspected of infection based on increased temper-
ature.12 14 Differences in inclusion criteria should also be 
discussed. The Feverkidstool derivation cohort included 
Dutch children aged 1 month to 15 years, whereas the 
OPPORTUNITY Study included Dutch and Israeli chil-
dren aged 1 month to 5 years. In addition, for the Fever-
kidstool development study, children who received 
antibiotics before the ED visit were excluded; for the 
OPPORTUNITY Study antibiotic use was no exclusion 
criterion.12 14 As mentioned/argued in the methods, we 
additionally excluded children admitted to intensive care 
(all referred from wards of other hospitals, n=14), and 
added 28 children aged 1–2 months from the OPPOR-
TUNITY subanalysis.
We recently confirmed the external validity of the Fever-
kidstool, but when procalcitonin (PCT) was added to the 
prediction model or when CRP was replaced by PCT the 
accuracy for predicting SBIs in febrile children did not 
improve.11 Another study updated the Feverkidstool by 
adding PCT and resistin, resulting in minimal changes in 
LR+ and LR− for different risk thresholds.13 In contrast 
to the two abovementioned Feverkidstool updates, our 
current study has shown that updating the Feverkidstool 
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with the assay does meaningfully improve the accuracy of 
the model. This further confirms our previous observation 
that the combination of CRP, TRAIL and IP-10 had higher 
diagnostic value in differentiating between bacterial and 
viral infections compared with PCT or CRP alone.14
Implications for clinical practice
Clinical signs and symptoms play an important role when 
physicians diagnose febrile children, but do not sufficiently 
differentiate between viral and bacterial infections. There-
fore, the use of diagnostic prediction models that include 
both clinical parameters and biomarkers is intuitive and 
helpful. The Feverkidstool provides two risk percentages; 
the risk for having pneumonia and the risk for having other 
SBIs. After further validation, a digital calculator should 
be constructed to facilitate potential clinical use. Both 
the assay and the Feverkidstool are designed to predict 
the outcome ‘bacterial infection’, and not the general 
level of illness of the child. Therefore, the outcome can 
be used to guide decisions on starting antibiotics or not, 
but cannot be used to guide decisions on how to adminis-
trate antibiotics or what type. We showed that the updated 
Feverkidstool has the most added value for patients in 
the low–moderate risk group, with predicted risk for SBIs 
below 40%. At thresholds of 2.5% and 10%, the reclassifi-
cation table showed substantial improvement in diagnosis. 
The cases with predicted risks between low to moderate 
(2.5 vs 40%) may be characterised by having intermediate 
values of CRP with higher diagnostic uncertainty. Adding 
two viral biomarkers to the prediction rule will provide 
an extra dimension to the model and therefore improve 
diagnosis especially for those cases. As a point-of-care test 
is under development, the manufacturer has not given an 
indication to the eventual cost yet. To optimise cost-effec-
tive use of the combination test, our results suggest that the 
added value of the assay is the highest in children with a 
predicted risk <40% as predicted by the original Feverkid-
stool. Utility studies are needed to determine the cut-off 
for the best clinical utility and cost-effectiveness.
Implications for future research
Since we have proven the accuracy of the updated Fever-
kidstool, the next step is to perform a prospective external 
validation and to evaluate its impact on resource use and 
antibiotic treatment. An important aspect is to define 
risk cut-offs for different settings in clinical practice, for 
example, young children and children with comorbidi-
ties. In addition, in order to optimise resource use, new 
biomarkers may benefit selected patient subgroups in 
particular (eg, selected on a set of clinical characteristics/
predicted risk) rather than in all febrile children. This 
targeted risk approach may also be applied to position 
the role of, for example, myxovirus resistance protein A 
and CRP.29
COnClusIOn
In conclusion, a new blood assay including viral and 
bacterial biomarkers, combined with a clinical prediction 
model is, in this study cohort, superior to the model with 
CRP only for predicting SBIs in preschool children. In 
children with low-to-moderate predicted risk of SBIs in 
particular, the updated Feverkidstool with the assay has 
the potential to optimise targeted antibiotic prescription 
and to prevent unnecessary use of antibiotics.
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